Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisRefining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous TocilizumabBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data SourcesEffect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsBiologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).The Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesSustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.Tocilizumab for treating juvenile idiopathic arthritis.Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database.Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: ResuROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.Tocilizumab: A Review in Rheumatoid Arthritis.Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.Weekly subcutaneous injection of tocilizumab in patients with rheumatoid arthritis.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.
P2860
Q24185797-0B75C995-A75A-4554-8FC3-65A74A45680FQ28080677-D3E6B118-B5C9-4D7C-85DA-F6CDACECD0B1Q30234528-1D7702C4-7C4A-4219-B51C-763E95A40307Q30235341-265A0C66-5598-4318-ACAF-46C9EA522CF9Q31137082-71F0B253-842A-47C2-BE64-B5761843232CQ31151183-E806D314-2E1D-4874-86C2-E4B3B0575655Q33725505-17D3EDBB-D879-4780-91FC-7176D570FA7AQ33809045-67DE5077-8AD6-48D2-A8B2-19ED9538BDF8Q36195284-00B79D9D-A520-4745-B66B-5A696B483589Q36249305-2366632F-00B4-467A-B720-6DD33401C048Q37320282-75B70CFA-194C-44B2-B4BF-D965D43C4463Q37453033-72F9AB8C-13BA-475F-B905-47ACEEE762B8Q38305522-FE8CB9C0-3C68-4995-BAE1-DE378A6B64C6Q38371450-671F3A96-A2A4-468A-96F5-FC1FA7BA0D2DQ38411334-C147D2D3-CCE7-4B51-B9D1-197C725DC351Q38617817-B6878FA1-F871-431D-91C6-3D16A6FA27A1Q38723988-F8E40C61-474E-429D-B7C7-E1B526E5E523Q38828876-453C44F8-5FF8-4F0A-A96C-0BA06965F28BQ39066090-27A38B8E-E0AC-460F-85F9-B43C6D4492BDQ40062836-985DDFBF-397C-4433-BB49-6B0DE11085DCQ40167433-4795AC35-65C8-4925-B8C5-BE056FE43A42Q40169728-54F8061B-9D2E-4E3A-8CB5-9E61BF500161Q40377000-143098B1-DB15-42D9-8BBD-1E50B52EDDCDQ42090806-DC83809F-7EF8-467A-80CC-F0E6EE4E9B95Q42146734-9FAE460D-BFFF-4359-A88F-8011A13F2E52Q43280791-038EC832-3180-445D-A4F0-F5DB1FA2E2C1Q47292924-1517327C-E144-4C4F-908F-618BAA560C38Q49518769-2168A6B0-9DCF-4003-A46D-A1D17AA74485Q49824861-DF6A9F07-571B-468B-AB6D-1AF5BBD80636Q50086845-C8F46AB9-5AD5-4794-AB76-9736AE5B59FDQ52675492-9343548E-7ECE-4533-A235-CFE2B079C10FQ55396986-086FF36A-9928-410C-9803-C5E236655CBC
P2860
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@ast
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@en
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@nl
type
label
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@ast
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@en
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@nl
prefLabel
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@ast
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@en
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@nl
P2093
P2860
P356
P1476
Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.
@en
P2093
Alan Kivitz
Beatriz M Zazueta
Clare Nasmyth-Miller
Federico Navarro-Sarabia
Joan T Merrill
Lucy Rowell
Michael Borofsky
Sebastião C Radominski
P2860
P304
P356
10.1002/ACR.22384
P50
P577
2014-11-01T00:00:00Z